Reuters logo
4 months ago
BRIEF-Antibe Therapeutics provides update on clinical development program for ATB-346
April 18, 2017 / 11:54 AM / 4 months ago

BRIEF-Antibe Therapeutics provides update on clinical development program for ATB-346

April 18 (Reuters) - Antibe Therapeutics Inc

* Antibe Therapeutics provides update on clinical development program for its lead drug, ATB-346

* Antibe Therapeutics Inc - earlier initiation of key GI safety clinical trial, facilitating earlier strategic exit discussions

* Antibe Therapeutics Inc says GI study to be completed at approximately year-end and other phase 2 study to be concluded by end of Q2/18

* Antibe - first phase 2, double-blind, upper GI safety study will be active comparator trial versus naproxen, will be conducted in 240 healthy volunteers Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below